Ireland - English - HPRA (Health Products Regulatory Authority)

alfasigma s.p.a - rifaximin - film-coated tablet - 550 milligram(s) - antibiotics; rifaximin

Israel - English - Ministry of Health

megapharm ltd - rifaximine - film coated tablets - rifaximine 200 mg - rifaximin - rifaximin - • casual treatment of diseases of grown-ups and youngsters from 12 years up, caused by bacteria in the gastrointestinal tract, sensitive to rifaximin:• hepatic encephalopathy • traveller’s diarrhea, caused by not-invasive enteropathogeneous bacteria.• non-complicated diverticular diseases.

Ireland - English - HPRA (Health Products Regulatory Authority)

alfa wassermann s.p.a. - rifaximin - film coated tablet - 550 milligram - antibiotics

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

special order - rifaximin - oral tablet - 550mg

United States - English - NLM (National Library of Medicine)

carton service, incorporated - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 550 mg

United States - English - NLM (National Library of Medicine)

cardinal health 107, llc - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 550 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re

United States - English - NLM (National Library of Medicine)

salix pharmaceuticals, inc. - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions ( 5.1), clinical pharmacology ( 12.4), clinical studies ( 14.1)]. x

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin, quantity: 550 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; titanium dioxide; glyceryl diisostearate; purified talc; hypromellose; propylene glycol; disodium edetate; colloidal anhydrous silica; iron oxide red; sodium starch glycollate type a - prevention of the recurrence of hepatic encephalopathy where other treatments have failed or are contraindicated.

Australia - English - Department of Health (Therapeutic Goods Administration)

norgine pty ltd - rifaximin, quantity: 200 mg - tablet, film coated - excipient ingredients: microcrystalline cellulose; glyceryl isostearate; sodium starch glycollate type a; colloidal anhydrous silica; purified talc; hypromellose; titanium dioxide; disodium edetate; propylene glycol; iron oxide red - xifaxan is indicated for the treatment of patients ( > = 12 years of age) with travellers? diarrhoea caused by non-invasive strains of escherichia coli (see ?precautions?, and ?clinical trials? ). travellers? diarrhoea describes a clinical picture predominantly observed in subjects travelling from developed to developing countries. it is most frequently caused by enterotoxigenic escherichia coli (etec), enteroaggregative e. coli (eaec) and other non-invasive pathogens.

United States - English - NLM (National Library of Medicine)

avera mckennan hospital - rifaximin (unii: l36o5t016n) (rifaximin - unii:l36o5t016n) - rifaximin 200 mg - to reduce the development of drug-resistant bacteria and maintain the effectiveness of xifaxan and other antibacterial drugs, xifaxan when used to treat infection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. when culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. in the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. xifaxan is indicated for the treatment of travelers’ diarrhea (td) caused by noninvasive strains of escherichia coli in adults and pediatric patients 12 years of age and older. limitations of use xifaxan should not be used in patients with diarrhea complicated by fever or blood in the stool or diarrhea due to pathogens other than escherichia coli [see warnings and precautions (5.1), clinical pharmacology (12.4), clinical studies (14.1)]. xifaxan is indicated for re